Cardiome jumps on fast-acting vernakalant; US filing plans still unknown
This article was originally published in Scrip
Executive Summary
Cardiome Pharma jumped 15.6% to close at $3.49 per share on 23 September after the company revealed data from an open-label study that showed patients in atrial fibrillation achieved conversion to normal sinus rhythm more than 10 times faster with intravenous vernakalant than with the oral therapies propafenone and flecainide.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.